drugset / Trial / NCT03375138

A Study Using Healthy Volunteers Comparing Belatacept Which Has Been Manufactured By 2 Different Processes

NCT03375138

Phase 1 Completed 84 enrolled Bristol-Myers Squibb
RandomizedParallel-groupOpen-labelTreatment

Summary

This study compares the movement of Belatacept drug products, whose active pharmaceutical ingredient has been manufactured by 2 different processes, into, through and out of the body (pharmacokinetics/PK) of healthy volunteers. Eligible participants will be randomly assigned to one of two groups, and will receive a single dose of a belatacept product once during a 4-day stay at a study site.

Timeline

Start
2017-12-04
Primary completion
2018-05-08
Completion
2019-04-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Belatacept Protein / enzyme biologic 10 mg/kg Intravenous

Indications

No indication recorded.